Roche (RHHBY) Plans to Launch 20 New Drugs to Tackle Major Societal Diseases

Sep 30, 2024

Roche (RHHBY, Financial) has announced its plan to introduce 20 new drugs to address some of the decade's most burdensome diseases. The company aims to double the number of patients using its medications between 2020 and 2029.

Roche is also striving to improve the success rate of its late-stage clinical trials by approximately one-fifth. The company has faced significant hurdles in getting its drugs approved in recent years. Following multiple setbacks in cancer and Alzheimer's treatments, CEO Thomas Schinecker is steering the company in a new direction.

These ambitious objectives result from more than a year of research and development overhaul at Roche. The firm is also entering the growing weight-loss drug market to compete with Novo Nordisk (NVO) and Eli Lilly (LLY).

Roche's current drug portfolio is expected to sustain the company at least until 2027. Thomas Schinecker has streamlined Roche's product pipeline, focusing on five key areas: cardiovascular diseases, ophthalmology, immunology, neurology, cancer, and hematology.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.